{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(1)"],"submitter":["Han J"],"pubmed_abstract":["<h4>Background</h4>Coronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitori"],"journal":["BMC infectious diseases"],"pagination":["1426"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12570802"],"repository":["biostudies-literature"],"pubmed_title":["Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2)."],"pmcid":["PMC12570802"],"pubmed_authors":["Kim DH","Noh E","Do H","Lee SY","Lee KO","Kim AR","Han J","Baek HJ","Kim JA","Lee JW"],"additional_accession":[]},"is_claimable":false,"name":"Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2).","description":"<h4>Background</h4>Coronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitori","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T10:32:43.153Z","creation":"2026-05-16T03:07:55.519Z"},"accession":"S-EPMC12570802","cross_references":{"pubmed":["41152822"],"doi":["10.1186/s12879-025-11753-1"]}}